Patients with human immunodeficiency virus (HIV)-associated diffuse large B-cell lymphoma (DLBCL) have poorer survival outcomes, even with combination antiretroviral therapy (cART), according to a study, which appeared in the Journal of Cancer.
To conduct this study, researchers retrospectively analyzed 78 HIV-infected patients with DLBCL from 2011 to 2019.
The researchers observed that most patients (74%) had poor performance status, elevated lactate dehydrogenase (LDH) levels (95%), B symptoms (74%), advanced Ann Arbor stages (81%), bulky diseases (64%), and extranodal involvement (70%) at diagnosis.
According to the results, factors correlated with decreased progression-free survival and overall survival in univariate analysis were unfavorable performance status and high international prognostic index. Specifically, elevated whole blood DNA copy number was associated with worse outcomes. “We did not observe a significant difference in survival between R-EPOCH and R-CHOP regimens,” the researchers wrote.
They concluded, “In our population, patients with HIV-associated DLBCL presented with aggressive characteristics and exhibited poor survival outcomes, even in the modern cART era.”